Limited Data for JAK Inhibitors in SSc Described in Study
9h agoen
From the article
In patients with systemic sclerosis, JAK inhibitors show comparable effectiveness to standard immunosuppressants, but many stop therapy due to treatment failure or adverse events. Medscape Medical News
Continue reading on MedscapeYou might also wanna read
Deep phenotyping of skin tissue remodeling in patients with systemic sclerosis treated with CD19-CAR T cells
doi.org·13d ago
Four JAK Inhibitors Show Positive Late-Stage Trial Results for Axial Spondyloarthritis Treatment
Positive results from late-stage clinical trials of four JAK inhibitors (filgotinib, gecacitinib, ivarmacitinib, and tofacitinib) for treati
mdsc.pe·17d agoA Study to Estimate Secukinumab Retention Rate in Psoriasis Patients With MASLD
clinicaltrials.gov·1d ago
A Study to Evaluate Luspatercept Utilization in Patients With Lower Risk Myelodysplastic Syndromes or Beta-thalassemia
clinicaltrials.gov·7d ago
A Study of Asciminib Safety and Efficacy in Young Adults With Chronic Myeloid Leukemia in the Gulf Region
clinicaltrials.gov·7d ago
ClinicalKey
clinicalkey.com·1mo ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.